Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Michael J Yellin"'
Autor:
Yong Lin, Jyoti Malhotra, Salma K Jabbour, Michael J Yellin, Malini Patel, Emmanuel Zachariah, Curtis Krier, Ankit Saxena
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c57b95046c624904b22223ed212fe7f7
Autor:
Tibor Keler, Balazs Halmos, Divij Mathew, Chandan Guha, Jeffrey M Levsky, E John Wherry, Josephine R Giles, Nitin Ohri, Shin Foong Ngiow, KC Wumesh, Madhur Garg, Haiying Cheng, Rasim Gucalp, William Bodner, Rafi Kabarriti, Claudia Gutierrez-Chavez, Adel Zakharia, Shalom Kalnicki, Michael J Yellin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/82d8c6fad55140779770b8cfcd282fbd
Autor:
John H. Sampson, Thomas A. Davis, Tibor Keler, Christopher D. Turner, Michael J. Yellin, Jennifer A. Green, Yi He, Laura Vitale, Scott Cruickshank, Maciej M. Mrugala, J. Paul Duic, Lynn S. Ashby, Rimas V. Lukas, Daniela A. Bota, Gordon Li, Louis B. Nabors, Karen L. Fink, David D. Tran, Donald M. O'Rourke, James J. Vredenburgh, Annick Desjardins, David A. Reardon
Figure A3 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e5523b850e66966a71fc3a40a27da45
https://doi.org/10.1158/1078-0432.22473939
https://doi.org/10.1158/1078-0432.22473939
Autor:
John H. Sampson, Thomas A. Davis, Tibor Keler, Christopher D. Turner, Michael J. Yellin, Jennifer A. Green, Yi He, Laura Vitale, Scott Cruickshank, Maciej M. Mrugala, J. Paul Duic, Lynn S. Ashby, Rimas V. Lukas, Daniela A. Bota, Gordon Li, Louis B. Nabors, Karen L. Fink, David D. Tran, Donald M. O'Rourke, James J. Vredenburgh, Annick Desjardins, David A. Reardon
Web Extra Material - 2 tables and 3 figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f78b399144b94b4e4ba8ee0ccc969b4
https://doi.org/10.1158/1078-0432.22473936.v1
https://doi.org/10.1158/1078-0432.22473936.v1
Autor:
John H. Sampson, Thomas A. Davis, Tibor Keler, Christopher D. Turner, Michael J. Yellin, Jennifer A. Green, Yi He, Laura Vitale, Scott Cruickshank, Maciej M. Mrugala, J. Paul Duic, Lynn S. Ashby, Rimas V. Lukas, Daniela A. Bota, Gordon Li, Louis B. Nabors, Karen L. Fink, David D. Tran, Donald M. O'Rourke, James J. Vredenburgh, Annick Desjardins, David A. Reardon
Purpose:Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive gli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1db99d990206b480a8975605cdc812ac
https://doi.org/10.1158/1078-0432.c.6528645.v1
https://doi.org/10.1158/1078-0432.c.6528645.v1
Autor:
Davide Bedognetti, Patrick Danaher, Mary L. Disis, Brent A. Hanks, Chihiro Morishima, Nina Bhardwaj, Anna C. Pavlick, Andres M. Salazar, Jason J. Luke, Ena Wang, Sarah Warren, Philip Friedlander, Lisa Lundgren, Steven P. Fling, Marc S. Ernstoff, Ana Belen Blazquez, Tibor Keler, Brendan D. Curti, Martin A. Cheever, Sreekumar Balan, Leonard A D'Amico, Michael J. Yellin, Thomas A. Davis, Bruce W. Hess, Bob Salim, Laura Vitale, Joseph M. Beechem, Elad Sharon, Darawan Rinchai, Nirasha Ramchurren, Brian R. Gastman, Andrea Crocker, Thomas Hawthorne, Mark R. Albertini
Publikováno v:
Nature Cancer. 1:1204-1217
Generating responses to tumor antigens poses a challenge for immunotherapy. This phase II trial (NCT02129075) tested fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment enhancement of responses to dendritic cell (DC)-targeting vaccines. We evaluat
Autor:
Danny N. Khalil, Tracey Rawls, Tibor Keler, Rachel E. Sanborn, Diego Alvarado, Lawrence J. Thomas, Laura Vitale, Maen Abdelrahim, Michael J. Yellin, Thomas U. Marron, Thomas Hawthorne, Nina Bhardwaj, Ralph J. Hauke, Mark H. O'Hara, Rodolfo Bordoni, Mark Rogalski, Nashat Y. Gabrail, Michael S. Gordon
Publikováno v:
Regular and young investigator award abstracts.
Background CDX-1140 is an agonist anti-CD40 mAb selected to optimize systemic exposure and hence tumor microenvironment (TME) ingress. CDX-1140 activity may be enhanced by combining with CDX-301 (recombinant Flt3L), a dendritic cell growth factor, or
Autor:
Li-Zhen He, Tibor Keler, Philip Golden, Laura Vitale, Tracey Rawls, Diane Young, Michael J. Yellin, Lawrence J. Thomas
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background CD27 ligation and PD-1 blockade elicit complementary signals mediating T cell activation and effector function. CD27 is constitutively expressed on most mature T cells and the interaction with its ligand, CD70, plays key roles in T cell co
Autor:
Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfgang Wick, Jennifer Green, Yi He, Christopher D Turner, Michael J Yellin, Tibor Keler, Thomas A Davis, Roger Stupp, John H Sampson, Jian Campian, Lawrence Recht, Samuel Goldlust, Kevin Becker, Gene Barnett, Garth Nicholas, Annick Desjardins, Tara Benkers, Naveed Wagle, Morris Groves, Santosh Kesari, Zsolt Horvath, Ryan Merrell, Richard Curry, James O'Rourke, David Schuster, Maciej Mrugala, Randy Jensen, John Trusheim, Glenn Lesser, Karl Belanger, Andrew Sloan, Benjamin Purow, Karen Fink, Jeffrey Raizer, Michael Schulder, Suresh Nair, Scott Peak, Alba Brandes, Nimish Mohile, Joseph Landolfi, Jon Olson, Ross Jennens, Paul DeSouza, Bridget Robinson, Marka Crittenden, Kent Shih, Alexandra Flowers, Shirley Ong, Jennifer Connelly, Costas Hadjipanayis, Pierre Giglio, Frank Mott, David Mathieu, Nathalie Lessard, Sanchez Juan Sepulveda, József Lövey, Helen Wheeler, Po-Ling Inglis, Claire Hardie, Daniela Bota, Maciej Lesniak, Jana Portnow, Bruce Frankel, Larry Junck, Reid Thompson, Lawrence Berk, John McGhie, David Macdonald, Frank Saran, Riccardo Soffietti, Deborah Blumenthal, Sá Barreto Costa Marcos André de, Anna Nowak, Nimit Singhal, Andreas Hottinger, Andrea Schmid, Gordan Srkalovic, David Baskin, Camilo Fadul, Louis Nabors, Renato LaRocca, John Villano, Nina Paleologos, Petr Kavan, Marshall Pitz, Brian Thiessen, Ahmed Idbaih, Jean Sébastien Frenel, Julien Domont, Oliver Grauer, Peter Hau, Christine Marosi, Jan Sroubek, Elizabeth Hovey, P.S. Sridhar, Lawrence Cher, Erin Dunbar, Thomas Coyle, Jane Raymond, Kevin Barton, Michael Guarino, Sumul Raval, Baldassarre Stea, Jorge Dietrich, Kirsten Hopkins, Sara Erridge, Joachim-Peter Steinbach, Losada Estela Pineda, Quintero Carmen Balana, Barco Berron Sonia del, Miklós Wenczl, Katalin Molnár, Katalin Hideghéty, Alexander Lossos, Linde Myra van, Ana Levy, Rosemary Harrup, William Patterson, Zarnie Lwin, Sith Sathornsumetee, E-Jian Lee, Jih-Tsun Ho, Steven Emmons, J. Paul Duic, Spencer Shao, Hani Ashamalla, Michael Weaver, Jose Lutzky, Nicholas Avgeropoulos, Wahid Hanna, Mukund Nadipuram, Gary Cecchi, Robert O'Donnell, Susan Pannullo, Jennifer Carney, Mark Hamilton, Mary MacNeil, Ronald Beaney, Michel Fabbro, Oliver Schnell, Rainer Fietkau, Guenther Stockhammer, Bela Malinova, Karel Odrazka, Martin Sames, Gil Miguel Gil, Evangelia Razis, Konstantin Lavrenkov, Guillermo Castro, Francisco Ramirez, Clarissa Baldotto, Fabiana Viola, Suzana Malheiros, Jason Lickliter, Stanislaw Gauden, Arunee Dechaphunkul, Iyavut Thaipisuttikul, Ziad Thotathil, Hsin-I Ma, Wen-Yu Cheng, Chin-Hong Chang, Fernando Salas, Pierre-Yves Dietrich, Christoph Mamot, Lakshmi Nayak, Shona Nag
Publikováno v:
The Lancet Oncology, Vol. 18, No 10 (2017) pp. 1373-1385
The Lancet. Oncology, vol 18, iss 10
The Lancet. Oncology, vol 18, iss 10
Summary Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6b5ae20a38597b1d233965368e0708
https://doi.org/10.5167/uzh-141081
https://doi.org/10.5167/uzh-141081
Autor:
Nashat Y. Gabrail, Thomas Hawthorne, Nina Bhardwaj, Michael S. Gordon, Danny N. Khalil, Mark H. O'Hara, Michael J. Yellin, Rachel E. Sanborn, Tibor Keler, Richard Gedrich, Laura Vitale, Mark Rogalski, Tracey Rawls, Tianshu Li
Publikováno v:
Cancer Research. 79:LB-194
CDX-1140 is an agonist CD40 mAb intended to promote priming of CD8+ effector T cells through activation of dendritic cells (DC), enhance macrophage tumoricidal activity, and mediate direct killing of CD40-expressing tumor cells. CDX-1140 is a human I